A systematic review and network meta-analysis of adjuvant therapy for curatively resected biliary tract cancers.

Conclusions: Although in the present analysis, we found no statistically significant improvements in os or rfs for capecitabine compared with gemox or gemcitabine, capecitabine can-until further prospective trials are completed-be considered the standard of care in the adjuvant setting based on a single randomized phase iii study. PMID: 32218664 [PubMed - as supplied by publisher]
Source: Current Oncology - Category: Cancer & Oncology Tags: Curr Oncol Source Type: research